Related references
Note: Only part of the references are listed.Safety and efficacy of depatuxizumab mafodotin plus temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial
Andrew B. Lassman et al.
NEURO-ONCOLOGY (2019)
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma
Alba A. Brandes et al.
ONCOLOGIST (2019)
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Kurt A. Schalper et al.
NATURE MEDICINE (2019)
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F. Cloughesy et al.
NATURE MEDICINE (2019)
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature
Salvatore Grisanti et al.
JOURNAL OF NEUROSURGICAL SCIENCES (2019)
A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma
Akihiro Tsuboi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma
Leszek Krolicki et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
Giuseppe Lombardi et al.
LANCET ONCOLOGY (2019)
A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma
Yoshitaka Narita et al.
NEURO-ONCOLOGY (2019)
Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas
Katherine B. Peters et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma
J. Duerinck et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma
Hui K. Gan et al.
NEURO-ONCOLOGY (2018)
Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine The Experience of the Italian Association of Neuro-Oncology
Francesco Pasqualetti et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
Phase 1/2 Trial of Temsirolimus and Sorafenib in the Treatment of Patients With Recurrent Glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
David Schiff et al.
CANCER (2018)
Retrospective study of nivolumab for patients with recurrent high grade gliomas
Megan Mantica et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients
J. N. Jakobsen et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study
Andrew Brenner et al.
NEURO-ONCOLOGY (2018)
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Annick Desjardins et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma
Shunsuke Shibao et al.
Oncotarget (2018)
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
Rimas V. Lukas et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors
Maria Dinche Johansen et al.
CANCER INVESTIGATION (2018)
Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma
Surasak Phuphanich et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma
Jayashree Kalpathy-Cramer et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma
Mark R. Gilbert et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series
Marc C. Chamberlain et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma Clinical Trial/Experimental Study
Lei Wang et al.
MEDICINE (2017)
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine
Katharina J. Wenger et al.
ONCOLOGY LETTERS (2017)
Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response
Robert Aiken et al.
ONCOTARGET (2017)
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial
Nabil Ahmed et al.
JAMA ONCOLOGY (2017)
Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas
Samantha N. Reiss et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study
Martin van den Bent et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma
Michael A. Badruddoja et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine
D. H. Heiland et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas
Yazmin Odia et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study
Nicholas Butowski et al.
NEURO-ONCOLOGY (2016)
Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma
Yasuharu Akasaki et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma
Robert A. Fenstermaker et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
Shiao-Pei Weathers et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Tamoxifen Induces Cytotoxic Autophagy in Glioblastoma
Christopher D. Graham et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2016)
AVAREG: a phase 2, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma
Alba A. Brandes et al.
NEURO-ONCOLOGY (2016)
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
Alba A. Brandes et al.
NEURO-ONCOLOGY (2016)
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
Nicholas Brown et al.
PLOS ONE (2016)
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
J. M. Sepulveda et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2015)
A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas
Yazmin Odia et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma
Keiichi Sakai et al.
JOURNAL OF NEUROSURGERY (2015)
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma
Elizabeth R. Gerstner et al.
NEURO-ONCOLOGY (2015)
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
Kathryn M. Field et al.
NEURO-ONCOLOGY (2015)
Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma
Ulrik Lassen et al.
NEURO-ONCOLOGY (2015)
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)
Andrew B. Lassman et al.
NEURO-ONCOLOGY (2015)
Treatment of recurrent malignant gliomas with 13-cis-retinoic acid naphthalene triazole
Pi-Feng Jia et al.
NEUROLOGICAL SCIENCES (2015)
First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity
Virgil E. J. C. Schijns et al.
VACCINE (2015)
A Phase III study of radiation therapy (RT) and O6-benzylguanine plus BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001
Deborah T. Blumenthal et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2015)
Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme
Martin K. Hunn et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Autologous T-cell Therapy for Cytomegalovirus as a Consolidative Treatment for Recurrent Glioblastoma
Andrea Schuessler et al.
CANCER RESEARCH (2014)
A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma
Wolfgang Wick et al.
CLINICAL CANCER RESEARCH (2014)
A Pilot Study of Hypofractionated Stereotactic Radiation Therapy and Sunitinib in Previously Irradiated Patients With Recurrent High-Grade Glioma
Evan J. Wuthrick et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry
Oscar Gallego et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option
Maya Flieger et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
The role of imaging in the management of progressive glioblastoma
Timothy Charles Ryken et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Residual tumor volume and patient survival following reoperation for recurrent glioblastoma
Raymund L. Yong et al.
JOURNAL OF NEUROSURGERY (2014)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal et al.
LANCET ONCOLOGY (2014)
Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy
David E. Piccioni et al.
NEURO-ONCOLOGY (2014)
Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccination for Recurrent Glioblastoma: A Phase II, Single Arm Trial
Orin Bloch et al.
NEURO-ONCOLOGY (2014)
Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab
Rifaquat Rahman et al.
NEURO-ONCOLOGY (2014)
Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas
V. Vaccaro et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Response to imatinib as a function of target kinase expression in recurrent glioblastoma
Marco Ronald Hassler et al.
SPRINGERPLUS (2014)
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience
Quintino Giorgio D'Alessandris et al.
ACTA NEUROCHIRURGICA (2013)
Human umbilical vein endothelial cell vaccine therapy in patients with recurrent glioblastoma
Minoru Tanaka et al.
CANCER SCIENCE (2013)
The impact of repeated surgery and adjuvant therapy on survival for patients with recurrent glioblastoma
Pasquale De Bonis et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2013)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme
Aida Muhic et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma
Yoshiki Arakawa et al.
NEUROLOGIA MEDICO-CHIRURGICA (2013)
Bevacizumab alone at 5 mg/kg in an every-3-week schedule for patients with recurrent glioblastomas: a single center experience
Gentian Kaloshi et al.
TUMORI (2013)
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO)
Miguel J. Gila et al.
ANTI-CANCER DRUGS (2012)
Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma†
Motoo Nagane et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2012)
Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery
Mark R. Gilbert et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma
Edward Pan et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Carboplatin and bevacizumab for recurrent malignant glioma
Maciej M. Mrugala et al.
ONCOLOGY LETTERS (2012)
A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma
Chen-Nen Chang et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2011)
Phase I Trial of a Personalized Peptide Vaccine for Patients Positive for Human Leukocyte Antigen-A24 With Recurrent or Progressive Glioblastoma Multiforme
Mizuhiko Terasaki et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Phase 2 Trial of Single-Agent Bevacizumab Given in an Every-3-Week Schedule for Patients With Recurrent High-Grade Gliomas
Jeffrey J. Raizer et al.
CANCER (2010)
Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas
Anne Clavreul et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2010)
Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma
Wenting Wu et al.
NEURO-ONCOLOGY (2010)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
Inhibition of TGF-beta 2 with AP 12009 in recurrent malignant gliomas: From preclinical to phase I/II studies
Peter Hau et al.
OLIGONUCLEOTIDES (2007)
EMBASE search strategies achieved for retrieving methodologically high sensitivity and specificity sound systematic reviews
Nancy L. Wilczynski et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2007)
Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine in patients with advanced glioma
H. Fakhrai et al.
CANCER GENE THERAPY (2006)
Age-specific search strategies for Medline
Monika Kastner et al.
JOURNAL OF MEDICAL INTERNET RESEARCH (2006)
Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021
HI Robins et al.
NEURO-ONCOLOGY (2006)
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
A Carpentier et al.
NEURO-ONCOLOGY (2006)
Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical phase I/II trial
R Yamanaka et al.
CLINICAL CANCER RESEARCH (2005)
Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey
RB Haynes et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Optimal search strategies for retrieving systematic reviews from Medline: analytical survey
VM Montori et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma
RO Dillman et al.
JOURNAL OF IMMUNOTHERAPY (2004)
Developing optimal search strategies for detecting clinically sound prognostic studies in MEDLINE: an analytic survey
Nancy L. Wilczynski et al.
BMC MEDICINE (2004)
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma:: A North American Brain Tumor Consortium study
KA Jaeckle et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
